Physician profile
Wiledade Augustin
NPI 1164809257
$2,040.47
in general payments reported to CMS, 2019-2025
20 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $701 · 2022: $311 · 2023: $388 · 2024: $500 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $314.82 | 2021-2025 | Zepbound, Jardiance |
| Novo Nordisk INC | $214.05 | 2021-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $199.83 | 2021-2022 | |
| Glaxosmithkline, LLC. | $166.36 | 2021-2023 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $125.00 | 2023 | Xarelto |
| Mylan Specialty L.P. | $125.00 | 2024 | Yupelri |
| Alnylam Pharmaceuticals INC. | $117.77 | 2024 | Amvuttra |
| Medtronic, INC. | $114.04 | 2024 | Linq II |
| E.R. Squibb & Sons, L.L.C. | $104.91 | 2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.69 | 2023 | Xifaxan |
| Pfizer INC. | $88.34 | 2021-2022 | |
| Amarin Pharma, INC. | $87.49 | 2021-2024 | |
| Abbvie INC. | $70.46 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.95 | 2022 | |
| Abbott Laboratories | $45.29 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $40.79 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.98 | 2021 | |
| Alk-Abello, INC | $18.99 | 2024 | Ragwitek, Odactra, Grastek |
| Novartis Pharmaceuticals Corporation | $16.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.41 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wiledade Augustin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.